A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension

[1]  M. S. Mcmurtry,et al.  Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer , 2013, Oncogene.

[2]  James D. Thomas,et al.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. , 2013, Annals of the American Thoracic Society.

[3]  J. Bigbee,et al.  Metabolic Gene Remodeling and Mitochondrial Dysfunction in Failing Right Ventricular Hypertrophy Secondary to Pulmonary Arterial Hypertension , 2013, Circulation. Heart failure.

[4]  L. Farkas,et al.  The monocrotaline model of pulmonary hypertension in perspective. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[5]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[6]  M. S. Mcmurtry,et al.  Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension , 2011, Journal of Molecular Medicine.

[7]  W. Sessa,et al.  The Role of Nogo and the Mitochondria–Endoplasmic Reticulum Unit in Pulmonary Hypertension , 2011, Science Translational Medicine.

[8]  N. Voelkel,et al.  Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. , 2010, American journal of respiratory and critical care medicine.

[9]  E. Michelakis,et al.  The role of mitochondria in pulmonary vascular remodeling , 2010, Journal of Molecular Medicine.

[10]  G. Lopaschuk,et al.  Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary Hypertension , 2010, Science Translational Medicine.

[11]  E. Ashley,et al.  New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy , 2010, Current opinion in cardiology.

[12]  C. Long,et al.  Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure , 2009, Circulation.

[13]  Kevin M. Ryan,et al.  p53 and metabolism , 2009, Nature Reviews Cancer.

[14]  Justin R. Cross,et al.  ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation , 2009, Science.

[15]  Kohtaro Abe,et al.  The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. , 2009, Chest.

[16]  I. Haber,et al.  The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle , 2009, Journal of Molecular Medicine.

[17]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[18]  J. Dyck,et al.  A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. , 2008, The Journal of thoracic and cardiovascular surgery.

[19]  Yi Tang,et al.  Acetylation Is Indispensable for p53 Activation , 2008, Cell.

[20]  S. Hunt,et al.  Right Ventricular Function in Cardiovascular Disease, Part II: Pathophysiology, Clinical Importance, and Management of Right Ventricular Failure , 2008, Circulation.

[21]  S. Hunt,et al.  Right Ventricular Function in Cardiovascular Disease, Part I: Anatomy, Physiology, Aging, and Functional Assessment of the Right Ventricle , 2008, Circulation.

[22]  W. Kaelin.  Faculty Opinions recommendation of Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. , 2008 .

[23]  I. Komuro,et al.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.

[24]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[25]  D. Srivastava.  Making or Breaking the Heart: From Lineage Determination to Morphogenesis , 2006, Cell.

[26]  J. Nyengaard,et al.  The total length of myocytes and capillaries, and total number of myocyte nuclei in the rat heart are time-dependently increased by growth hormone. , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[27]  Y. Kagaya,et al.  Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. , 2005, Journal of the American College of Cardiology.

[28]  P. Schumacker,et al.  Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. , 2005, Cell metabolism.

[29]  Massimo Zeviani,et al.  Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. , 2005, Cell metabolism.

[30]  M. Lerman,et al.  DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF-1α in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IX , 2004, Molecular and Cellular Biology.

[31]  D. Mccrory,et al.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[32]  B. Brüne,et al.  p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). , 2004, The Biochemical journal.

[33]  Ling Song,et al.  Glycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53* , 2003, Journal of Biological Chemistry.

[34]  J. Yoshikawa,et al.  Carvedilol inhibits pressure-induced increase in oxidative stress in coronary smooth muscle cells. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[35]  H. Morita,et al.  Carvedilol Decreases Elevated Oxidative Stress in Human Failing Myocardium , 2002, Circulation.

[36]  J. Sandoval,et al.  Right ventricular ischemia in patients with primary pulmonary hypertension. , 2001, Journal of the American College of Cardiology.

[37]  W. Dai,et al.  Reactive Oxygen Species-induced Phosphorylation of p53 on Serine 20 Is Mediated in Part by Polo-like Kinase-3* , 2001, The Journal of Biological Chemistry.

[38]  Y. Rojanasakul,et al.  Vanadate Induces p53 Transactivation through Hydrogen Peroxide and Causes Apoptosis* , 2000, The Journal of Biological Chemistry.

[39]  Xianglin Shi,et al.  The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. , 2000, American journal of physiology. Cell physiology.

[40]  F. Muders,et al.  Animal models of chronic heart failure. , 2000, Pharmacological research.

[41]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[42]  J. Conte,et al.  Increased p53 protein expression in human failing myocardium. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[43]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.

[44]  D. Livingston,et al.  Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its α Subunit* , 1996, The Journal of Biological Chemistry.

[45]  K. M. Popov,et al.  Diversity of the Pyruvate Dehydrogenase Kinase Gene Family in Humans * , 1995, The Journal of Biological Chemistry.

[46]  G. Semenza,et al.  Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. , 1995, Biochemical and biophysical research communications.

[47]  R. Ferrari,et al.  Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure. , 1989, Cardiovascular research.

[48]  S. Bishop,et al.  Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. , 1970, The American journal of physiology.